| Revision as of 14:29, 16 December 2019 editCitation bot (talk | contribs)Bots5,408,830 editsm Add: url. | You can use this bot yourself. Report bugs here.| Activated by User:Nemo bis | via #UCB_webform← Previous edit |
Latest revision as of 16:50, 21 March 2024 edit undoKimen8 (talk | contribs)Extended confirmed users5,112 edits MOS:BOLD |
| (11 intermediate revisions by 10 users not shown) |
| Line 1: |
Line 1: |
|
|
{{short description|Class of antidepressants}} |
|
] (original brand name '''Remeron''').]] |
|
] (original brand name Remeron)]] |
|
|
|
|
|
'''Noradrenergic and specific serotonergic antidepressants''' ('''NaSSAs''') are a class of ]s used primarily as ]s.<ref name="Julien2004">{{cite book | author = Robert M. Julien | title = A Primer Of Drug Action: A Comprehensive Guide To The Actions, Uses, And Side Effects Of Psychoactive Drugs | url = https://books.google.com/books?id=fhNkIsK4y9QC&pg=PA286 | accessdate = 23 April 2012 | date = 17 September 2004 | publisher = Macmillan | isbn = 978-0-7167-0615-1 | pages = 286}}</ref> They act by ] the ] and certain ]s such as ] and ],<ref name="Julien2004" /> but also ],<ref name="Julien2004" /> ], and/or ] in some cases. By blocking α<sub>2</sub>-adrenergic ]s and ]s, NaSSAs enhance ] and ] ] in the ] involved in ] regulation,<ref name="Julien2004" /> notably ]-mediated transmission.<ref name="HalesShahrokh2009">{{cite book | author1 = Robert E. Hales | author2 = Narriman C. Shahrokh | author3 = Alan F. Schatzberg |author4=Charles B. Nemeroff | title = Study Guide to Psychopharmacology: A Companion to the American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition | url = https://books.google.com/books?id=--BsJw_A7UwC&pg=PA202 | accessdate = 23 April 2012 | date = 28 April 2009 | publisher = American Psychiatric Pub | isbn = 978-1-58562-354-9 | page = 202}}</ref> In addition, due to their blockade of certain serotonin receptors, serotonergic neurotransmission is not facilitated in unwanted areas, which prevents the incidence of many ]s often associated with ] (SSRI) antidepressants;<ref name="Julien2004" /><ref name="Publishers1998">{{cite book | author = Bentham Science Publishers | title = Current Pharmaceutical Design | url = https://books.google.com/books?id=LjNh9ASGehUC&pg=PA298 | accessdate = 23 April 2012 | date = August 1998 | publisher = Bentham Science Publishers | page = 298}}</ref> hence, in part, the "specific serotonergic" label of NaSSAs.<ref name="HalesShahrokh2009" /> |
|
'''Noradrenergic and specific serotonergic antidepressants''' ('''NaSSAs''') are a class of ]s used primarily as ]s.<ref name="Julien2004">{{cite book | author = Robert M. Julien | title = A Primer Of Drug Action: A Comprehensive Guide To The Actions, Uses, And Side Effects Of Psychoactive Drugs | url = https://books.google.com/books?id=fhNkIsK4y9QC&pg=PA286 | access-date = 23 April 2012 | date = 17 September 2004 | publisher = Macmillan | isbn = 978-0-7167-0615-1 | pages = 286}}</ref> They act by ] the ] and certain ]s such as ] and ],<ref name="Julien2004" /> but also ],<ref name="Julien2004" /> ], and/or ] in some cases. By blocking α<sub>2</sub>-adrenergic ]s and ]s, NaSSAs enhance ] and ] ] in the ] involved in ] regulation,<ref name="Julien2004" /> notably ]-mediated transmission.<ref name="HalesShahrokh2009">{{cite book | author1 = Robert E. Hales | author2 = Narriman C. Shahrokh | author3 = Alan F. Schatzberg |author4=Charles B. Nemeroff | title = Study Guide to Psychopharmacology: A Companion to the American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition | url = https://books.google.com/books?id=--BsJw_A7UwC&pg=PA202 | access-date = 23 April 2012 | date = 28 April 2009 | publisher = American Psychiatric Pub | isbn = 978-1-58562-354-9 | page = 202}}</ref> In addition, due to their blockade of certain serotonin receptors, serotonergic neurotransmission is not facilitated in unwanted areas, which prevents the incidence of many ]s often associated with ] (SSRI) antidepressants;<ref name="Julien2004" /><ref name="Publishers1998">{{cite book | author = Bentham Science Publishers | title = Current Pharmaceutical Design | url = https://archive.org/details/bub_gb_LjNh9ASGehUC | access-date = 23 April 2012 | date = August 1998 | publisher = Bentham Science Publishers | page = }}</ref> hence, in part, the "specific serotonergic" label of NaSSAs.<ref name="HalesShahrokh2009" /> |
|
|
|
|
|
==List of NaSSAs== |
|
==List of NaSSAs== |
| Line 8: |
Line 9: |
|
* ] (CGS-7525A) |
|
* ] (CGS-7525A) |
|
* ] (ORG-50,081) |
|
* ] (ORG-50,081) |
|
* ] (Bolvidon, Norval, Tolvon)<ref name="Carlstedt2009">{{cite book | author = Roland A. Carlstedt | title = Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research | url = https://books.google.com/books?id=4Tkdm1vRFbUC&pg=PA290 | accessdate = 23 April 2012 | date = 14 December 2009 | publisher = Springer Publishing Company | isbn = 978-0-8261-1094-7 | page = 290}}</ref> |
|
* ] (Bolvidon, Norval, Tolvon)<ref name="Carlstedt2009">{{cite book | author = Roland A. Carlstedt | title = Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research | url = https://books.google.com/books?id=4Tkdm1vRFbUC&pg=PA290 | access-date = 23 April 2012 | date = 14 December 2009 | publisher = Springer Publishing Company | isbn = 978-0-8261-1094-7 | page = 290}}</ref> |
|
* ] (Norset, Remeron, Avanza, Zispin)<ref name="Carlstedt2009" /> |
|
* ] (Norset, Remeron, Avanza, Zispin)<ref name="Carlstedt2009" /> |
|
* ] (Tecipul) |
|
* ] (Tecipul) |
| Line 14: |
Line 15: |
|
Notably, all of these compounds are ] and are also classified as ]s (TeCAs) based on their ]s. |
|
Notably, all of these compounds are ] and are also classified as ]s (TeCAs) based on their ]s. |
|
|
|
|
|
], a structurally novel NaSSA with an improved ] profile (e.g., no ] effects, etc.), was reported in 2012.<ref name="pmid22178752">{{cite journal |vauthors=Millan MJ, Mannoury la Cour C, Chanrion B, etal | title = S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 340 | issue = 3 | pages = 750–64 |date=March 2012 | pmid = 22178752 | doi = 10.1124/jpet.111.187468 | url = https://semanticscholar.org/paper/d14a817669e7e86445729af340ab5d47ee9df486 }}</ref><ref name="pmid22178753">{{cite journal |vauthors=Dekeyne A, Brocco M, Loiseau F, etal | title = S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 340 | issue = 3 | pages = 765–80 |date=March 2012 | pmid = 22178753 | doi = 10.1124/jpet.111.187534 | url = https://semanticscholar.org/paper/4cf5619d492835d7ceac87268ac38c0cad335212 }}</ref> It has completed preliminary ] and may go on to undergo ]s. |
|
], a structurally novel NaSSA with an improved ] profile (e.g., no ] effects, etc.), was reported in 2012.<ref name="pmid22178752">{{cite journal |vauthors=Millan MJ, Mannoury la Cour C, Chanrion B, etal | title = S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 340 | issue = 3 | pages = 750–64 |date=March 2012 | pmid = 22178752 | doi = 10.1124/jpet.111.187468 | s2cid = 8546314 }}</ref><ref name="pmid22178753">{{cite journal |vauthors=Dekeyne A, Brocco M, Loiseau F, etal | title = S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 340 | issue = 3 | pages = 765–80 |date=March 2012 | pmid = 22178753 | doi = 10.1124/jpet.111.187534 | s2cid = 11363664 }}</ref> It has completed preliminary ] and may go on to undergo ]s. |
|
|
|
|
|
==See also== |
|
==See also== |
| Line 28: |
Line 29: |
|
|
|
|
|
==Further reading== |
|
==Further reading== |
|
* {{cite journal | author = Kent JM | title = SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression | journal = Lancet | volume = 355 | issue = 9207 | pages = 911–8 |date=March 2000 | pmid = 10752718 | doi = 10.1016/S0140-6736(99)11381-3 }} |
|
* {{cite journal | author = Kent JM | title = SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression | journal = Lancet | volume = 355 | issue = 9207 | pages = 911–8 |date=March 2000 | pmid = 10752718 | doi = 10.1016/S0140-6736(99)11381-3 | s2cid = 27686300 | doi-access = free }} |
|
|
|
|
|
|
==External links== |
|
|
*{{Commonscatinline|Noradrenergic and specific serotonergic antidepressants}} |
|
|
|
|
|
{{Antidepressants}} |
|
{{Antidepressants}} |
| Line 37: |
Line 40: |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
Media related to Noradrenergic and specific serotonergic antidepressants at Wikimedia Commons